Summary - Funding Rounds

Founding Date

2008
IOmet Pharma is a subsidiary of Merck

IOmet Pharma Income Statement

Annual

GBPFY, 2015FY, 2016FY, 2017FY, 2018

EBITDA

(2.9m)(17.0m)(13.7m)(23.2m)

EBIT

(2.9m)(17.0m)(13.7m)(23.2m)

Pre tax profit

(2.9m)(17.0m)(13.7m)(23.1m)

Income tax expense

1.3m(84.6k)(60.4k)

Net Income

(1.6m)(17.1m)(13.7m)(23.2m)

IOmet Pharma Balance Sheet

Annual

GBPFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

8.8m2.7m765.4k1.3m5.1m1.7m34.7m18.2m

Accounts Receivable

137.2k320.8k522.0k95.8k

Current Assets

8.9m7.8m6.1m2.9m6.2m2.1m34.8m18.5m

PP&E

16.9k11.2k12.4k5.8k2.6k

Total Assets

8.9m7.8m6.1m2.9m6.2m2.1m34.8m18.5m

Accounts Payable

63.2k92.7k393.0k597.9k179.7k39.6k405.1k117.6k

Current Liabilities

63.2k92.7k393.0k597.9k509.4k13.8m25.2m9.6m

Total Liabilities

63.2k92.7k393.0k597.9k509.4k13.8m25.2m9.6m

Common Stock

392.0392.0392.0392.0457.0513.0513.0513.0

Retained Earnings

(3.7m)(7.1m)(8.7m)(28.7m)(42.3m)(65.6m)

Total Equity

8.9m7.7m5.7m2.3m5.7m(11.7m)9.6m8.9m

Financial Leverage

1 x1 x1.1 x1.3 x1.1 x-0.2 x3.6 x2.1 x

IOmet Pharma Cash Flow

Annual

GBPFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(1.6m)(17.1m)(13.7m)(23.2m)

Income Taxes Paid

1.3m